On February 25, SinocellTech reported that its independently developed recombinant humanized anti- PD-1 IgG4 monoclonal antibody, fenolimab (Anyouping , SCT – I10A ), combined with the recombinant humanized anti -VEGF monoclonal antibody bevacizumab, received official approval from the China National Medical Products Administration ( NMPA ) for the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma ( HCC ) who have not received prior systemic therapy (Press release, Sinocelltech, FEB 25, 2025, View Source [SID1234656253]). Following its approval as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma, SinocellTech secured its second indication in the PD-1 arena .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!